Bio-Rad Laboratories, Inc.
Health
Performance
3.1
Risk
Sell
Buy
Curious about the Scores? Learn more.

Bio-Rad Laboratories, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

01.07.2026
Shaky at first, now slowly moving toward steady ground.
01.07.2026
Health’s picking up. Numbers look cleaner, cash flow tighter.
19.06.2026
Momentum tanked. Clearly underperforming.
22.05.2026
Calmer waters ahead. Risk signals cooling off.
BIO
Bio-Rad Laboratories, Inc.
301.90
-0.81%
3.1
Sell
Buy
Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Bio-Rad Laboratories, Inc. do? Business model and key facts

Get the full picture of Bio-Rad Laboratories, Inc.: what it builds, where it operates, and how it makes money.

Bio-Rad Laboratories, Inc. Profile

Sector: Healthcare

Industry: Medical - Devices

Employees (FY): 7450

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

shop
Company facts
Norman D. Schwartz
CEO
7450
Employees worldwide
shop
Performance
23.6%
Last 12 months
-54.83%
Last 5 years
shop
Growth
$2.58B
Revenue year
$759.90M
Net income
shop
Valuation
$8.23B
Market Cap
10.87
Price/Earnings Ratio

Stocks related to Bio-Rad Laboratories, Inc.

Selected based on industry alignment and relative market positioning.

BRKR
Bruker Corporation
56.17
-3.54%
6.5
Sell
Buy
Bruker Corporation
GKOS
Glaukos Corporation
155.46
-0.87%
5.8
Sell
Buy
Glaukos Corporation
MASI
Masimo Corporation
179.95
+0.00%
5.5
Sell
Buy
Masimo Corporation
LIVN
LivaNova PLC
79.21
-1.85%
3.8
Sell
Buy
LivaNova PLC
IRTC
iRhythm Technologies, Inc.
111.37
+0.44%
5.6
Sell
Buy
iRhythm Technologies, Inc.

Events and news impacting Bio-Rad Laboratories, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Bio-Rad Laboratories, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.